Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
The Conversation logo

Over the past few weeks, the UK government has gradually eased national lockdown measures. As the economy reopens, and people return to workplaces and spend more time in shops, pubs and restaurants, the number of contacts an individual has with other people will inevitably increase.

Since then, there has been an increase in COVID-19 cases following the lowest recorded estimate in June, as well as spikes in transmission in certain areas. In response, rather than locking down the whole country again, the government has brought in local lockdowns in affected areas.

National lockdown has a significant indirect effect on people’s health: fewer people go to hospital emergency departments when needed and vaccination and cancer screening programmes are delayed. Local lockdowns, therefore, aim to control the spread of the virus in a specific area in response to a local spike of infections. They may be the best option we have for managing the pandemic prior to a vaccine becoming available.

Read the full article on The Conversation website, written by Lakshmi Manoharan, Centre for Tropical Medicine & Global Health.

Oxford is a subscribing member of The ConversationFind out how you can write for The Conversation.

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.